Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Aug 15 (Reuters) - In the latest setback for Pfizer's (PFE.N), opens new tab sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients ...

Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with ...

・Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...